151 related articles for article (PubMed ID: 20417730)
1. Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.
Colavita I; Esposito N; Martinelli R; Catanzano F; Melo JV; Pane F; Ruoppolo M; Salvatore F
Biochim Biophys Acta; 2010 Oct; 1804(10):1974-87. PubMed ID: 20417730
[TBL] [Abstract][Full Text] [Related]
2. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Donato NJ; Wu JY; Stapley J; Lin H; Arlinghaus R; Aggarwal BB; Shishodia S; Albitar M; Hayes K; Kantarjian H; Talpaz M
Cancer Res; 2004 Jan; 64(2):672-7. PubMed ID: 14744784
[TBL] [Abstract][Full Text] [Related]
4. Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Okabe S; Tauchi T; Nakajima A; Sashida G; Gotoh A; Broxmeyer HE; Ohyashiki JH; Ohyashiki K
Stem Cells Dev; 2007 Jun; 16(3):503-14. PubMed ID: 17610380
[TBL] [Abstract][Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.
Buchi F; Pastorelli R; Ferrari G; Spinelli E; Gozzini A; Sassolini F; Bosi A; Tombaccini D; Santini V
Leuk Res; 2011 Jul; 35(7):921-31. PubMed ID: 21382639
[TBL] [Abstract][Full Text] [Related]
7. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
[No Abstract] [Full Text] [Related]
9. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
von Bubnoff N; Peschel C; Duyster J
Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
[TBL] [Abstract][Full Text] [Related]
10. Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Tipping AJ; Deininger MW; Goldman JM; Melo JV
Exp Hematol; 2003 Nov; 31(11):1073-80. PubMed ID: 14585372
[TBL] [Abstract][Full Text] [Related]
11. Resistance in the land of molecular cancer therapeutics.
Shannon KM
Cancer Cell; 2002 Aug; 2(2):99-102. PubMed ID: 12204529
[TBL] [Abstract][Full Text] [Related]
12. Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells.
Colavita I; Esposito N; Quintarelli C; Nigro E; Pane F; Ruoppolo M; Salvatore F
Proteomics; 2013 Aug; 13(16):2414-8. PubMed ID: 23754495
[TBL] [Abstract][Full Text] [Related]
13. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
15. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
[TBL] [Abstract][Full Text] [Related]
17. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
[TBL] [Abstract][Full Text] [Related]
18. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Melo JV; Chuah C
Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121
[TBL] [Abstract][Full Text] [Related]
19. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
20. Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.
Preisinger C; Schwarz JP; Bleijerveld OB; Corradini E; Müller PJ; Anderson KI; Kolch W; Scholten A; Heck AJ
Leukemia; 2013 Mar; 27(3):743-6. PubMed ID: 22976128
[No Abstract] [Full Text] [Related]
[Next] [New Search]
